Goldman Sachs maintains a Buy rating on Sysmex but cuts target price to ¥1,700

Overview

This report is Goldman Sachs' commentary on Sysmex's FY3/26 results and FY3/27 guidance. FY3/26 results were in line with the revised guidance, and underlying fourth-quarter performance was considered broadly solid; however, FY3/27 operating profit guidance was materially below Goldman Sachs' prior forecast and market consensus, reflecting deteriorating China business conditions and rising cost pressure.

Core views

Goldman Sachs' core view is that near-term earnings uncertainty remains, especially from China pricing pressure and rising SG&A costs; however, Sysmex holds global leading shares in core products such as hematology, coagulation, and urinalysis, and long-term demand is supported by population aging in developed economies and improvements in healthcare infrastructure in emerging markets. If China headwinds peak and company-wide earnings resume growth, the stock could re-rate, so Goldman maintains a Buy rating.

Analysis framework

The report uses earnings comparison, guidance decomposition, earnings forecast revisions, and relative valuation. Goldman compares FY3/26 actual results with revised guidance, 3Q guidance, and prior forecasts, and compares FY3/27 management guidance with Goldman Sachs estimates and I/B/E/S consensus; the target price is based on FY3/28E EV/EBITDA and then discounted versus the average valuation of the global medical technology sector.

Methodology notes

• Valuation methodsEV/EBITDA relative valuation

  Estimating target price based on FY3/28E EV/EBITDA

  Goldman Sachs uses the global medical technology sector's FY3/28E average EV/EBITDA multiple of 11.0x and applies a 20% discount to derive Sysmex's 12-month target price of ¥1,700.

• earnings qualityUnderlying operating profit adjustment

  Assessing core profitability by excluding one-off items

  The report notes that FY3/26 operating profit included ¥11.2 billion in impairment losses; excluding this impact, underlying operating profit was slightly above the guidance given at 3Q, indicating the fourth quarter was broadly solid.

• factor analysisGS Factor Profile

  Growth, financial returns, valuation multiples, and composite factor percentiles

  Goldman Sachs' factor framework compares a stock's growth, financial returns, valuation multiples, and composite characteristics against the market and industry peers to provide investment context.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Sysmex (6869.T)

  core coverage name

  Strengths

  Holds global leading shares in hematology, coagulation, and urinalysis products; long-term demand is supported by aging populations, improved healthcare infrastructure in emerging markets, and medium- to long-term opportunities in immunoassay, medical robotics, and Alzheimer's disease diagnostics.

  Weaknesses

  Near-term profit guidance was below expectations, weighed by China pricing pressure, higher SG&A expenses, and inflation.

  Comparison

  The target price is based on the global medical technology sector's FY3/28E average EV/EBITDA multiple of 11.0x with a 20% discount; the report argues the stock has already corrected significantly and looks inexpensive versus historical and peer comparisons.

  Risks

  Deteriorating China business conditions, price declines, geopolitical and supply chain changes, global healthcare cost containment policies, intensifying competition, foreign exchange volatility, higher inflation pressure, and weaker-than-expected capital expenditure trends.

• TOPIX

  market relative performance benchmark

  Strengths

  Used to measure 6869.T's share price performance relative to the Japanese market.

  Weaknesses

  The chart shows 6869.T underperformed TOPIX over the 6-month and 12-month horizons.

  Comparison

  The report chart shows 6869.T's 3-month absolute return was about 3.2% and its relative return versus TOPIX was about 1.6%; its 6-month absolute return was about -14.2% and relative return about -25.7%; its 12-month absolute return was about -49.1% and relative return about -63.7%.

  Risks

  If overall risk appetite in the Japanese market weakens, it could further hinder valuation recovery.

Key data

• Report date2026-05-14 11:13PM JSTDisclosure time on the report cover page.
• RatingBuyGoldman Sachs maintains a Buy rating.
• 12-month target price¥1,700Cut from the previous ¥1,850.
• Current price¥1,343Price disclosed on the report cover page.
• Implied upside26.6%Based on the target price and current price.
• FY3/26 salesapproximately ¥500 billionIn line with revised guidance and close to Goldman Sachs' prior forecast of ¥499 billion.
• FY3/26 operating profitapproximately ¥51.8 billionIn line with the revised guidance announced on April 28, which included impairment losses.
• FY3/27 sales guidance¥535 billionBroadly in line with Goldman Sachs' prior forecast of ¥531 billion and the I/B/E/S consensus of ¥539 billion.
• FY3/27 operating profit guidance¥58 billionBelow Goldman Sachs' prior forecast of ¥72 billion and the I/B/E/S consensus of ¥74 billion.
• Earnings forecast revisionFY3/27-FY3/30 operating profit forecasts cut by 2%-17%Mainly due to lower China business price assumptions and higher SG&A expenses.
• Market capitalizationapproximately ¥837.5 billion / $5.3 billionKey data on the report cover page.
• Enterprise valueapproximately ¥859.8 billion / $5.4 billionKey data on the report cover page.

Impact & implications

The report is mildly positive for investment implications but emphasizes short-term pressure. The weaker-than-expected FY3/27 profit guidance may weigh on near-term earnings expectations and market sentiment; however, the target price still implies 26.6% upside, and Goldman Sachs believes the stock could re-rate once China headwinds peak and value-chain reforms plus business portfolio reviews improve profitability.

Risks

• Deteriorating China business conditions and downward pressure on standardized testing prices.
• Rising SG&A expenses and inflation putting pressure on margins.
• Geopolitical risks and supply chain changes.
• Global healthcare reforms and cost containment policies.
• Intensifying competition, especially from rising local players in emerging markets that may drive price declines.
• Foreign exchange volatility.
• Higher inflation pressure.
• Capital expenditure trends weaker than expected.

What to watch

• Management's comments at the May 15 earnings briefing on whether the assumptions underlying the China business guidance are achievable.
• The possibility that value-chain reforms and business portfolio reviews improve profitability.
• Whether China headwinds have peaked and whether localization expansion and product line extensions can drive earnings to bottom out.
• Whether core earnings trends remain solid in quarterly results.
• Medium-term growth in immunoassay, development progress in medical robotics, and sales trends for new hematology products after their U.S. launch.
• Long-term commercialization progress in Alzheimer's disease diagnostics, genomics analysis, and diagnostic reagents.